Video

Dr. Zorn discusses 3-year data on Aquablation

Author(s):

Urology Times staff

“I think Aquablation is safe. It’s efficacious, especially in these large prostates,” says Kevin Zorn, MD, FRCSC, FACS.

In this video, Kevin Zorn, MD, FRCSC, FACS, discusses the findings and takeaways of the study, “Aquablation for benign prostatic hyperplasia in large prostates (80-150CC): 3-year results,” which was presented during the 2021 American Urological Association annual meeting. Zorn is an associate professor of urology at the University of Montreal, Canada.

Related Videos
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Wayne Kuang, MD, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Business meeting | Image Credit: © Panumas - stock.adobe.com
Related Content
FDA logo
January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely
Catch up on all the notable drug and device approvals in urology over the past year.
male patient sitting in clinic room while doctor talks with him
May 23rd 2023

Dr. Gange discusses data on the UroLift System for BPH

Urology Times staff
The data were presented at the recent American Urological Association Annual Meeting.
Phase 1/2 trial launches of Focal One robotic HIFU for BPH
October 9th 2024

Phase 1/2 trial launches of Focal One robotic HIFU for BPH

Hannah Clarke
“While there are other treatment options available for treating BPH, there remains a significant need for much less invasive treatment approaches that can preserve and protect the integrity of the urethra and other critical structures," says Ryan Rhodes.
Destigmatizing Urology: Dr. McVary discusses enlarged prostates
February 8th 2022

Destigmatizing Urology: Dr. McVary discusses enlarged prostates

Urology Times staff
“Even though there [are] many therapies that one can do, it's not a sign of anything ominous for most men,” says Kevin T. McVary, MD, FACS.
FDA grants 510(k) clearance to AI-powered robotic system for Aquablation therapy
August 21st 2024

FDA grants 510(k) clearance to AI-powered robotic system for Aquablation therapy

Hannah Clarke
A full market release of the HYDROS System is expected within the current quarter.
AUA, GURS, SUFU amend guideline for incontinence after prostate treatment
July 10th 2024

AUA, GURS, SUFU amend guideline for incontinence after prostate treatment

Hannah Clarke
The guideline includes 38 recommendations on managing incontinence following treatment for localized prostate cancer or benign prostatic hyperplasia.
© 2025 MJH Life Sciences

All rights reserved.